Dose-response effect of somatostatin-14 on human basal pancreatic hormones.
The effect of increased doses of Somatostatin-14 (3, 10, 30, 100, 300 micrograms/h) on basal release of insulin, pancreatic glucagon and pancreatic polypeptide (PP) was investigated on eight normal volunteers. Levels of Somatostatin-like immunoreactivity (SLI) was determined in order to correlate the increased SLI levels with the degree of islet hormone inhibition (r = 0.9947, p less than 0.01). By increasing the basal levels of SLI by one-third, a significant inhibition (p less than 0.01) of insulin, glucagon, and PP was noted (78.5, 78.6, 75.2%, respectively, on basal levels). The maximal effect was obtained with 300 micrograms/h for insulin, with 30 micrograms/h for glucagon and 100 micrograms/h for PP. In evaluating the relative inhibitory potency of somatostatin, expressed as ED50, the theoretic potency of somatostatin on each peptide had similar values, ranging from 30 to 10 micrograms/h. The present data show that a minimal peripheric increase in SLI is able to regulate basal islet pancreatic hormones.
D000328:Adult; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D005260:Female; D005934:Glucagon / Q000097:blood; D006801:Humans; D007260:Infusion Pumps; D007328:Insulin / Q000097:blood; D007515:Islets of Langerhans / Q000187:drug effects; D008297:Male; D010187:Pancreatic Hormones / Q000097:blood*; D010191:Pancreatic Polypeptide / Q000097:blood; D013004:Somatostatin / Q000008:administration & dosage / Q000494:pharmacology*
D007328:Insulin; D010187:Pancreatic Hormones; D013004:Somatostatin; D010191:Pancreatic Polypeptide; D005934:Glucagon